Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 217 to 225 of 225 entries
Sorted by: Best Match Show Resources per page
Discussion: The FDA is Unprepared for Personalized Medicine.

Biostatistics (Oxford, England)

Tabarrok A.
PMID: 28633317
Biostatistics. 2017 Jul 01;18(3):403-404. doi: 10.1093/biostatistics/kxx018.

No abstract available.

Cite
Tabarrok A. Discussion: The FDA is Unprepared for Personalized Medicine. Biostatistics. 2017;18(3):403-404doi: 10.1093/biostatistics/kxx018.
Tabarrok, A. (2017). Discussion: The FDA is Unprepared for Personalized Medicine. Biostatistics (Oxford, England), 18(3), 403-404. https://doi.org/10.1093/biostatistics/kxx018
Tabarrok, Alex. "Discussion: The FDA is Unprepared for Personalized Medicine." Biostatistics (Oxford, England) vol. 18,3 (2017): 403-404. doi: https://doi.org/10.1093/biostatistics/kxx018
Tabarrok A. Discussion: The FDA is Unprepared for Personalized Medicine. Biostatistics. 2017 Jul 01;18(3):403-404. doi: 10.1093/biostatistics/kxx018. PMID: 28633317.
Copy Download .nbib Format: NLM
A New Day Dawns for Direct-to-Consumer Marketing.

Genetic testing and molecular biomarkers

Mena C, Terry SF.
PMID: 28498774
Genet Test Mol Biomarkers. 2017 May;21(5):273-274. doi: 10.1089/gtmb.2017.29031.sjt.

No abstract available.

Cite
Mena C, Terry SF. A New Day Dawns for Direct-to-Consumer Marketing. Genet Test Mol Biomarkers. 2017;21(5):273-274doi: 10.1089/gtmb.2017.29031.sjt.
Mena, C., & Terry, S. F. (2017). A New Day Dawns for Direct-to-Consumer Marketing. Genetic testing and molecular biomarkers, 21(5), 273-274. https://doi.org/10.1089/gtmb.2017.29031.sjt
Mena, Claire, and Terry, Sharon F. "A New Day Dawns for Direct-to-Consumer Marketing." Genetic testing and molecular biomarkers vol. 21,5 (2017): 273-274. doi: https://doi.org/10.1089/gtmb.2017.29031.sjt
Mena C, Terry SF. A New Day Dawns for Direct-to-Consumer Marketing. Genet Test Mol Biomarkers. 2017 May;21(5):273-274. doi: 10.1089/gtmb.2017.29031.sjt. PMID: 28498774.
Copy Download .nbib Format: NLM
Approaching ethical, legal and social issues of emerging forensic DNA phenotyping (FDP) technologies comprehensively: Reply to 'Forensic DNA phenotyping: Predicting human appearance from crime scene material for investigative purposes' by Manfred Kayser.

Forensic science international. Genetics

Toom V, Wienroth M, M'charek A, Prainsack B, Williams R, Duster T, Heinemann T, Kruse C, Machado H, Murphy E.
PMID: 26832996
Forensic Sci Int Genet. 2016 May;22:e1-e4. doi: 10.1016/j.fsigen.2016.01.010. Epub 2016 Jan 19.

No abstract available.

Cite
Toom V, Wienroth M, M'charek A, et al. Approaching ethical, legal and social issues of emerging forensic DNA phenotyping (FDP) technologies comprehensively: Reply to 'Forensic DNA phenotyping: Predicting human appearance from crime scene material for investigative purposes' by Manfred Kayser. Forensic Sci Int Genet. 2016;22:e1-e4doi: 10.1016/j.fsigen.2016.01.010.
Toom, V., Wienroth, M., M'charek, A., Prainsack, B., Williams, R., Duster, T., Heinemann, T., Kruse, C., Machado, H., & Murphy, E. (2016). Approaching ethical, legal and social issues of emerging forensic DNA phenotyping (FDP) technologies comprehensively: Reply to 'Forensic DNA phenotyping: Predicting human appearance from crime scene material for investigative purposes' by Manfred Kayser. Forensic science international. Genetics, 22e1-e4. https://doi.org/10.1016/j.fsigen.2016.01.010
Toom, Victor, et al. "Approaching ethical, legal and social issues of emerging forensic DNA phenotyping (FDP) technologies comprehensively: Reply to 'Forensic DNA phenotyping: Predicting human appearance from crime scene material for investigative purposes' by Manfred Kayser." Forensic science international. Genetics vol. 22 (2016): e1-e4. doi: https://doi.org/10.1016/j.fsigen.2016.01.010
Toom V, Wienroth M, M'charek A, Prainsack B, Williams R, Duster T, Heinemann T, Kruse C, Machado H, Murphy E. Approaching ethical, legal and social issues of emerging forensic DNA phenotyping (FDP) technologies comprehensively: Reply to 'Forensic DNA phenotyping: Predicting human appearance from crime scene material for investigative purposes' by Manfred Kayser. Forensic Sci Int Genet. 2016 May;22:e1-e4. doi: 10.1016/j.fsigen.2016.01.010. Epub 2016 Jan 19. PMID: 26832996.
Copy Download .nbib Format: NLM
Persistent Underutilization of BRCA1/2 Testing Suggest the Need for New Approaches to Genetic Testing Delivery.

Journal of the National Cancer Institute

McCarthy AM.
PMID: 30753664
J Natl Cancer Inst. 2019 Aug 01;111(8):751-753. doi: 10.1093/jnci/djz009.

No abstract available.

Cite
McCarthy AM. Persistent Underutilization of BRCA1/2 Testing Suggest the Need for New Approaches to Genetic Testing Delivery. J Natl Cancer Inst. 2019;111(8):751-753doi: 10.1093/jnci/djz009.
McCarthy, A. M. (2019). Persistent Underutilization of BRCA1/2 Testing Suggest the Need for New Approaches to Genetic Testing Delivery. Journal of the National Cancer Institute, 111(8), 751-753. https://doi.org/10.1093/jnci/djz009
McCarthy, Anne Marie. "Persistent Underutilization of BRCA1/2 Testing Suggest the Need for New Approaches to Genetic Testing Delivery." Journal of the National Cancer Institute vol. 111,8 (2019): 751-753. doi: https://doi.org/10.1093/jnci/djz009
McCarthy AM. Persistent Underutilization of BRCA1/2 Testing Suggest the Need for New Approaches to Genetic Testing Delivery. J Natl Cancer Inst. 2019 Aug 01;111(8):751-753. doi: 10.1093/jnci/djz009. PMID: 30753664; PMCID: PMC6695316.
Copy Download .nbib Format: NLM
Letting the genome out of the bottle.

The New England journal of medicine

Audeh MW.
PMID: 18494080
N Engl J Med. 2008 May 15;358(20):2184-5; author reply 2185.

No abstract available.

Cite
Audeh MW. Letting the genome out of the bottle. N Engl J Med. 2008;358(20):2184-5; author reply 2185
Audeh, M. W. (2008). Letting the genome out of the bottle. The New England journal of medicine, 358(20), 2184-5; author reply 2185.
Audeh, M William. "Letting the genome out of the bottle." The New England journal of medicine vol. 358,20 (2008): 2184-5; author reply 2185.
Audeh MW. Letting the genome out of the bottle. N Engl J Med. 2008 May 15;358(20):2184-5; author reply 2185. PMID: 18494080.
Copy Download .nbib Format: NLM
Does the law require reinterpretation and return of revised genomic results?.

Genetics in medicine : official journal of the American College of Medical Genetics

Clayton EW, Appelbaum PS, Chung WK, Marchant GE, Roberts JL, Evans BJ.
PMID: 33420344
Genet Med. 2021 May;23(5):833-836. doi: 10.1038/s41436-020-01065-x. Epub 2021 Jan 08.

No abstract available.

Cite
Clayton EW, Appelbaum PS, Chung WK, et al. Does the law require reinterpretation and return of revised genomic results?. Genet Med. 2021;23(5):833-836doi: 10.1038/s41436-020-01065-x.
Clayton, E. W., Appelbaum, P. S., Chung, W. K., Marchant, G. E., Roberts, J. L., & Evans, B. J. (2021). Does the law require reinterpretation and return of revised genomic results?. Genetics in medicine : official journal of the American College of Medical Genetics, 23(5), 833-836. https://doi.org/10.1038/s41436-020-01065-x
Clayton, Ellen Wright, et al. "Does the law require reinterpretation and return of revised genomic results?." Genetics in medicine : official journal of the American College of Medical Genetics vol. 23,5 (2021): 833-836. doi: https://doi.org/10.1038/s41436-020-01065-x
Clayton EW, Appelbaum PS, Chung WK, Marchant GE, Roberts JL, Evans BJ. Does the law require reinterpretation and return of revised genomic results?. Genet Med. 2021 May;23(5):833-836. doi: 10.1038/s41436-020-01065-x. Epub 2021 Jan 08. PMID: 33420344; PMCID: PMC8107115.
Copy Download .nbib Format: NLM
Policy before practice: genetic discrimination reviewed.

American journal of pharmacogenomics : genomics-related research in drug development and clinical practice

Epps PG.
PMID: 14672522
Am J Pharmacogenomics. 2003;3(6):405-18. doi: 10.2165/00129785-200303060-00008.

The value of genetics in medicine has been steadily developing with our increasing knowledge of the human genome. Genetic testing to determine disease risk or potential drug effects is set to become more commonplace. With this comes increasing concern...

Cite
Epps PG. Policy before practice: genetic discrimination reviewed. Am J Pharmacogenomics. 2003;3(6):405-18doi: 10.2165/00129785-200303060-00008.
Epps, P. G. (2003). Policy before practice: genetic discrimination reviewed. American journal of pharmacogenomics : genomics-related research in drug development and clinical practice, 3(6), 405-18. https://doi.org/10.2165/00129785-200303060-00008
Epps, Phyllis Griffin. "Policy before practice: genetic discrimination reviewed." American journal of pharmacogenomics : genomics-related research in drug development and clinical practice vol. 3,6 (2003): 405-18. doi: https://doi.org/10.2165/00129785-200303060-00008
Epps PG. Policy before practice: genetic discrimination reviewed. Am J Pharmacogenomics. 2003;3(6):405-18. doi: 10.2165/00129785-200303060-00008. PMID: 14672522.
Copy Download .nbib Format: NLM
Genetic risk prediction--are we there yet?.

The New England journal of medicine

Kraft P, Hunter DJ.
PMID: 19369656
N Engl J Med. 2009 Apr 23;360(17):1701-3. doi: 10.1056/NEJMp0810107. Epub 2009 Apr 15.

No abstract available.

Cite
Kraft P, Hunter DJ. Genetic risk prediction--are we there yet?. N Engl J Med. 2009;360(17):1701-3doi: 10.1056/NEJMp0810107.
Kraft, P., & Hunter, D. J. (2009). Genetic risk prediction--are we there yet?. The New England journal of medicine, 360(17), 1701-3. https://doi.org/10.1056/NEJMp0810107
Kraft, Peter, and Hunter, David J. "Genetic risk prediction--are we there yet?." The New England journal of medicine vol. 360,17 (2009): 1701-3. doi: https://doi.org/10.1056/NEJMp0810107
Kraft P, Hunter DJ. Genetic risk prediction--are we there yet?. N Engl J Med. 2009 Apr 23;360(17):1701-3. doi: 10.1056/NEJMp0810107. Epub 2009 Apr 15. PMID: 19369656.
Copy Download .nbib Format: NLM
Evaluation of Patient Demographics in Clinical Cancer Genomic Testing.

The journal of applied laboratory medicine

Winston-McPherson GN, Mathias PC, Lockwood CM, Greene DN.
PMID: 33398333
J Appl Lab Med. 2021 Jan 12;6(1):119-124. doi: 10.1093/jalm/jfaa219.

BACKGROUND: Inequitable use of next-generation sequencing (NGS) testing for cancer risk and treatment can contribute to heath disparity. Consequently, it is important to assess the population receiving this testing. In this article, we characterize the population receiving both germline...

Cite
Winston-McPherson GN, Mathias PC, Lockwood CM, et al. Evaluation of Patient Demographics in Clinical Cancer Genomic Testing. J Appl Lab Med. 2021;6(1):119-124doi: 10.1093/jalm/jfaa219.
Winston-McPherson, G. N., Mathias, P. C., Lockwood, C. M., & Greene, D. N. (2021). Evaluation of Patient Demographics in Clinical Cancer Genomic Testing. The journal of applied laboratory medicine, 6(1), 119-124. https://doi.org/10.1093/jalm/jfaa219
Winston-McPherson, Gabrielle N, et al. "Evaluation of Patient Demographics in Clinical Cancer Genomic Testing." The journal of applied laboratory medicine vol. 6,1 (2021): 119-124. doi: https://doi.org/10.1093/jalm/jfaa219
Winston-McPherson GN, Mathias PC, Lockwood CM, Greene DN. Evaluation of Patient Demographics in Clinical Cancer Genomic Testing. J Appl Lab Med. 2021 Jan 12;6(1):119-124. doi: 10.1093/jalm/jfaa219. PMID: 33398333.
Copy Download .nbib Format: NLM
Showing 217 to 225 of 225 entries